Vilafinil: Enhance Cognitive Performance with Precision
| Product dosage: 200 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.86 | $55.90 (0%) | 🛒 Add to cart |
| 60 | $1.15 | $111.80 $68.80 (38%) | 🛒 Add to cart |
| 100 | $0.81 | $186.33 $80.84 (57%) | 🛒 Add to cart |
| 200 | $0.75 | $372.67 $150.50 (60%) | 🛒 Add to cart |
| 300 | $0.69 | $559.00 $208.12 (63%) | 🛒 Add to cart |
| 500 | $0.65
Best per pill | $931.67 $322.50 (65%) | 🛒 Add to cart |
Vilafinil is a high-purity pharmaceutical agent indicated for the promotion of wakefulness and the enhancement of cognitive function in adults experiencing excessive sleepiness due to narcolepsy, obstructive sleep apnea, or shift work sleep disorder. Its primary mechanism of action involves the selective modulation of neurotransmitter systems, promoting alertness without the generalized stimulant effects associated with traditional psychostimulants. This profile makes it a valuable tool in neuroenhancement protocols under professional supervision.
Features
- Active Pharmaceutical Ingredient: Modafinil
- Standard Dosage Form: 100 mg and 200 mg film-coated tablets
- High Bioavailability: Rapid and consistent absorption profile
- Chemical Purity: Manufactured under strict cGMP guidelines
- Pharmacokinetics: Peak plasma concentration reached within 2–4 hours post-administration
- Half-Life: Approximately 12–15 hours, supporting once-daily dosing
Benefits
- Promotes sustained wakefulness and reduces subjective feelings of sleepiness without significant euphoria or agitation.
- Enhances executive functions, including working memory, cognitive flexibility, and planning capabilities.
- Improves attention span and task engagement in individuals with attention deficits related to sleep disorders.
- Supports occupational and academic performance by mitigating fatigue-induced cognitive decline.
- Exhibits a favorable safety and tolerability profile relative to traditional stimulant medications.
- May contribute to improved quality of life for patients with chronic sleep-wake disorders.
Common use
Vilafinil is primarily prescribed for the treatment of excessive daytime sleepiness associated with diagnosed medical conditions such as narcolepsy, obstructive sleep apnea (with adjunctive continuous positive airway pressure), and shift work sleep disorder. Off-label, it is sometimes utilized in contexts requiring enhanced vigilance and cognitive endurance, though such use should only occur under explicit medical guidance and diagnostic justification.
Dosage and direction
The standard recommended dosage for Vilafinil is 200 mg taken orally once daily, preferably in the morning. For shift work sleep disorder, administration should occur approximately one hour prior to the start of the work shift. Dosage adjustment may be necessary in elderly patients or those with severe hepatic impairment, with a recommended reduction to 100 mg daily. Tablets should be swallowed whole with water and may be taken with or without food, though consistent administration relative to meals is advised for stable pharmacokinetics.
Precautions
Patients should be advised that Vilafinil may cause dizziness or blurred vision, potentially affecting the ability to drive or operate machinery. Caution is recommended in individuals with a history of hypertension, cardiac arrhythmias, or other cardiovascular conditions. Psychiatric symptoms such as anxiety, agitation, or hallucinations have been reported and should be monitored. Use during pregnancy or lactation is not recommended unless the potential benefit justifies the potential risk to the fetus or infant. Regular hepatic function monitoring is advised during prolonged therapy.
Contraindications
Vilafinil is contraindicated in patients with known hypersensitivity to modafinil or any excipients in the formulation. It should not be used in individuals with symptomatic ischemic heart disease, left ventricular hypertrophy, or mitral valve prolapse accompanied by clinical symptoms. Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of hypertensive crisis. Severe hepatic impairment without dosage adjustment is also a contraindication.
Possible side effects
Common adverse reactions (≥1%) include headache, nausea, nervousness, anxiety, insomnia, dizziness, and diarrhea. Less frequently, palpitations, elevated blood pressure, dry mouth, and rash may occur. Rare but serious side effects include Stevens-Johnson Syndrome, angioedema, multiorgan hypersensitivity reactions, and psychiatric symptoms such as aggression or suicidal ideation. Any severe or persistent reaction should prompt discontinuation and medical consultation.
Drug interactions
Vilafinil is a moderate inducer of CYP3A4 and an inhibitor of CYP2C19. Concurrent administration with substrates of these enzymes may necessitate dosage adjustments. Examples include reduced efficacy of cyclosporine, ethinylestradiol, and certain antifungals or anticonvulsants. Conversely, Vilafinil may increase plasma concentrations of drugs such as diazepam, phenytoin, or tricyclic antidepressants. Concomitant use with other CNS stimulants may potentiate sympathetic effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is close to the time of the next scheduled dose. Doubling the dose to compensate for a missed one is not recommended. For shift workers, if a dose is missed prior to a work shift, it may be taken at the beginning of the shift, but subsequent dosing should return to the regular schedule.
Overdose
Symptoms of overdose may include insomnia, agitation, confusion, tachycardia, hypertension, and gastrointestinal distress. In severe cases, delirium or seizures may occur. There is no specific antidote; management should consist of symptomatic and supportive care, including cardiovascular monitoring and activated charcoal administration if ingestion was recent. Hemodialysis is not expected to be effective due to high protein binding.
Storage
Store at room temperature (15–30°C) in a dry place, protected from light and moisture. Keep the container tightly closed and out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Dispose of unused medication via a pharmacy take-back program or according to local regulations.
Disclaimer
This information is intended for educational purposes and does not constitute medical advice. Vilafinil is a prescription medication and should only be used under the supervision of a qualified healthcare professional. Always follow the guidance of your prescribing physician and refer to the official prescribing information for complete details regarding use, risks, and benefits.
Reviews
Clinical studies and patient reports generally reflect positive outcomes regarding vigilance and cognitive enhancement, particularly in narcolepsy and shift work disorder populations. Some users note mild side effects such as headache or insomnia, which often subside with continued use. Overall satisfaction is frequently tied to proper diagnostic alignment and adherence to prescribed dosing. Long-term users emphasize the importance of periodic medical reevaluation to ensure ongoing suitability and monitoring.